ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
ADMA Biologics's pe ratio was 18.8× on Nov 11, 2026, against 22.6× a year earlier. Over the last 2 years it ranged from 11.7× to 142.8×, with a median of 21.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 18.8× | −2.6 |
| 2025 | Dec 31, 2025 | 21.5× | −39.8 |
| 2024 | Dec 31, 2024 | 61.3× | – |
See a number that looks wrong?